Management Team

Vijay Aggarwal, Ph.D.
Chief Executive Officer
Dr. Aggarwal is CEO of Aureon Laboratories. He has over 20 years of senior executive experience in both pharmaceutical services and clinical diagnostics. Previously, he served as President of AAI Development Services, a company dedicated to providing contract research and development services to the pharmaceutical and biotech industry. In addition, Dr. Aggarwal has held the positions of President, Quest Diagnostic Ventures where he had responsibility for new technology, new business models, clinical trials testing, and direct to consumer strategies. Prior to Quest Diagnostics, Dr. Aggarwal held positions with SmithKline Beecham Clinical Laboratories (SBCL), including direct responsibility for all of SBCL’s U.S.-based laboratories as Executive Vice President of Laboratories, Vice President of Managed Care and several general management, laboratory operational and business development roles.

Robert Shovlin
President & Chief Operating Officer
Mr. Shovlin joined Aureon Laboratories in June of 2005 as Vice President of Sales and Marketing. Prior to joining Aureon, he was the Executive Director of anatomic pathology for Quest Diagnostics Incorporated (NYSE: DGX), a $5 billion clinical laboratory. In this role he had national responsibility for Quest Diagnostics’ $500 million anatomic pathology business. Mr. Shovlin also previously held a regional sales director position managing $1 billion of health plan customer business for Quest Diagnostics. Before working at Quest Diagnostics, he held several sales and sales management roles at DIANON Systems, Inc. a $200 million specialty anatomic pathology laboratory. Robert is a former Captain in the United States Marine Corps who holds a B.S. from Penn State University and an M.B.A. from Rutgers University.

Michael Donovan, M.D., Ph.D.
Chief Scientific Officer
Dr. Donovan is board certified in anatomic and clinical pathology. He received his medical degree from the University of Medicine and Dentistry of New Jersey and his Ph.D. in cell and developmental biology from Rutgers University, New Brunswick, NJ. Dr. Donovan completed his residency at the New York Hospital where he also served as Chief Resident of Autopsy Pathology. Dr. Donovan completed a postdoctoral fellowship at Harvard Medical School and a one-year Pediatric Pathology Fellowship at Children’s Hospital, Boston. Prior to joining Aureon, Dr. Donovan held positions as Assistant Professor at Harvard Medical School, Senior Director of Molecular Pathology at Millennium Pharmaceuticals, and Senior Vice President at Incyte Genomics.

Ricardo Mesa-Tejada, M.D.
Vice President, Pathology & Medical Director
Dr. Mesa-Tejada trained in anatomic pathology at the College of Physicians and Surgeons of Columbia University where he served as full-time faculty for ten years and presently holds a part-time appointment as Associate Clinical Professor. While primarily engaged in breast cancer research at Columbia, his emphasis on the use immunologic and molecular tissue localization techniques led to his recruitment by MetPath Laboratories, presently Quest Diagnostics, where he founded and directed the Molecular Tissue Pathology Laboratory at its Teterboro, NJ headquarters for ten years. Dr. Mesa-Tejada has been a member of several NIH/NCI scientific review panels and presently serves on the Medical Advisory Board of the Norma F. Phriem Breast Care Center, Fairfield/Bridgeport, CT, and the Boards of the Society for Applied Immunohistochemistry and American Fertility Services, New York, NY. Prior to joining Aureon, he was a consultant to several specialty pathology laboratories and biotechnology companies, and was Senior VP - Health Sciences at Thieme Consulting, Inc., the consulting branch of Thieme Associates, a New York-based global financial services group.
Charles J. DiComo, Ph.D.
Director of Laboratories
Dr. DiComo has been with Aureon since its inception and was instrumental in the original design and build-out of the corporate offices and CLIA-certified / CAP-accredited clinical laboratories, including the company’s Prognostic/Diagnostic Services and R&D facilities. Prior to joining Aureon, Dr. DiComo was Laboratory Head/Research Associate in the Division of Molecular Pathology at Memorial Sloan-Kettering Cancer Center as a Leukemia and Lymphoma Society Research Special Fellow. In this capacity, Dr. DiComo managed and coordinated day-to-day operations of the molecular and histopathology laboratories, assisted in the scientific direction of post-doctoral fellows, graduate students, and technicians, conducted independent research as part of the New York p53 Consortium, and developed state-of-the-art molecular pathology methodologies in conjunction with Dr. Carlos Cordon-Cardo. Prior to MSKCC, Dr. DiComo was a Damon Runyon-Walter Winchell Fellow at Columbia University in the Department of Biological Sciences under the tutelage of Dr. Carol Prives. Dr. DiComo completed his graduate studies at Cold Spring Harbor Laboratories through a joint program with the University of New York at Stony Brook. His work has been published in numerous peer-reviewed journals, such as Clinical Cancer Research, Oncogene and Cell. Charles holds a B.S. in molecular and cellular biology and an M.S. in molecular and cellular genetics from Long Island University – C.W. Post Campus, as well as a Ph.D. in genetics from the State University of New York at Stony Brook.